Stock DYN DYNE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Dyne Therapeutics, Inc.

Equities

DYN

US26818M1080

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
24.73 USD +4.37% Intraday chart for Dyne Therapeutics, Inc. +3.65% +85.94%
Mar. 25 Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell MT
Mar. 25 Dyne Therapeutics, Inc. Announces Management Changes CI

Evolution of the average Target Price on Dyne Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ad06ce608c2fe.zP569YCX09OVWPcY5T6NRwT8Wlj-lnQz0LE1P6R_pdg.k8k3nunF56rCAZ5uoGvYEnWjIhacwEIegIdXe9E3xKG4jwyw49Dhl6Jgog~dc0bc49b03469c5cd0170ba8128a0928

Analyst Recommendations on Dyne Therapeutics, Inc.

Chardan Raises Price Target on Dyne Therapeutics to $31 From $20 on Increased Confidence in Lead Assets for DM1, DMD, Keeps Buy Rating MT
Piper Sandler Adjusts Price Target on Dyne Therapeutics to $29 From $27, Maintains Overweight Rating MT
Stifel Adjusts Price Target on Dyne Therapeutics to $41 From $35, Maintains Buy Rating MT
Oppenheimer Adjusts Dyne Therapeutics Price Target to $47 From $44, Maintains Outperform Rating MT
H.C. Wainwright Initiates Dyne Therapeutics With Buy Rating, Price Target is $36 MT
Raymond James Adjusts Price Target on Dyne Therapeutics to $56 From $27, Keeps Strong Buy Rating MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Traders Await Rate Cut Hints in Policy Meeting Readout MT
Chardan Adjusts Price Target on Dyne Therapeutics to $20 From $17, Maintains Buy Rating MT
Raymond James Upgrades Dyne Therapeutics to Strong Buy From Outperform, Adjusts Price Target to $27 From $16 MT
Oppenheimer Initiates Coverage on Dyne Therapeutics With Outperform Rating, $34 Price Target MT
Guggenheim Starts Dyne Therapeutics at Buy With $33 Price Target MT
JPMorgan Adjusts Price Target on Dyne Therapeutics to $18 From $24, Maintains Overweight Rating MT
Raymond James Adjusts Price Target on Dyne Therapeutics to $16 From $15, Maintains Outperform Rating MT
Chardan Research Initiates Coverage on Dyne Therapeutics With Buy Rating, $17 Price Target MT
Raymond James Starts Dyne Therapeutics at Outperform With $15 Price Target MT
Piper Sandler Lowers Dyne Therapeutics' Price Target to $12 From $16, Maintains Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.73 USD
Average target price
37.56 USD
Spread / Average Target
+51.86%
High Price Target
56 USD
Spread / Highest target
+126.45%
Low Price Target
25 USD
Spread / Lowest Target
+1.09%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Dyne Therapeutics, Inc.

Chardan Research
Stifel Nicolaus
Piper Sandler
Oppenheimer
HC Wainwright
Raymond James
Guggenheim
JPMorgan Chase

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. DYN Stock
  4. Consensus Dyne Therapeutics, Inc.